VIROGENICS, INC.

Company Information

Company Name
VIROGENICS, INC.
Address
PO BOX 2702
DEL MAR, CA, 92014-
Phone
n/a
URL
n/a
DUNS
146101196
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$2,797,997.00
6
SBIR Phase II
$2,309,520.00
1
STTR Phase I
$599,936.00
1
Chart code to be here

Award List

  1. FIV Vectors for the Treatment of Hemophilia A

    Amount: $2,309,520.00

    DESCRIPTION (provided by applicant): Although several labs including ours have demonstrated the feasibility of gene therapy for hemophilia A in animal models, long-term expression of the transgene at ...

    SBIR Phase II 2010 Department of Health and Human Services
  2. Lentiviral Vector Gene Therapy for CD45 Deliver

    Amount: $748,800.00

    DESCRIPTION (provided by the applicant): The overall goal of this project is to address the need for an effective therapy for patients with severe combined immunodeficiency due to loss of CD45 functio ...

    SBIR Phase I 2003 Department of Health and Human Services
  3. FIV Vectors for the Treatment of Hemophilia A

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The current standard of care for hemophilia A is treatment with intravenous FVIII protein infusions, either prophylacticly or during bleeding episodes. Prophylacti ...

    SBIR Phase I 2005 Department of Health and Human Services
  4. Non-Integrating FIV Vectors for HIV Vaccines

    Amount: $600,002.00

    DESCRIPTION (provided by applicant): The diagnosis of 15,000 new cases of HIV infections every day demonstrates the pressing need for a prophylactic HIV vaccine to prevent further spread of the pandem ...

    SBIR Phase I 2006 Department of Health and Human Services
  5. Hemophilia A: Intrathymic Delivery for Tolerance and Longterm Expression of FVIII

    Amount: $149,881.00

    DESCRIPTION (provided by applicant): The current standard of care for hemophilia A is treatment with intravenous human factor VIII (hFVIII) protein infusions, either prophylactically or during bleedin ...

    SBIR Phase I 2007 Department of Health and Human Services
  6. A Novel Immune Modulator/ Adjuvant for HIV Vaccines

    Amount: $599,314.00

    DESCRIPTION (provided by applicant): During the past two decades of HIV vaccine development, a wide variety of AIDS vaccine strategies have been explored. Among the many tested, DNA and viral vector-b ...

    SBIR Phase I 2008 Department of Health and Human Services
  7. Modulation of the Innate Immune System by Fisetin for the Treatment of AD

    Amount: $599,936.00

    DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most p ...

    STTR Phase I 2013 Department of Health and Human Services
  8. siRNA Modulation of the Immune Response

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): A major goal expressed by NIAID and other agencies charged with development of the U.S. biodefense research strategy is a broad spectrum activity that mitigates c ...

    SBIR Phase I 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government